The Expanding Role of Vascular Endothelial Growth Factor Inhibitors in Ophthalmology
- 31 January 2012
- journal article
- review article
- Published by Elsevier BV in Mayo Clinic Proceedings
- Vol. 87 (1), 77-88
- https://doi.org/10.1016/j.mayocp.2011.10.001
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- Ranibizumab and Bevacizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2011
- Efficacy of Intravitreal Bevacizumab for Stage 3+ Retinopathy of PrematurityThe New England Journal of Medicine, 2011
- Pegaptanib sodium as maintenance therapy in neovascular age-related macular degeneration: the LEVEL studyBritish Journal of Ophthalmology, 2010
- Age-Related Macular DegenerationThe New England Journal of Medicine, 2008
- The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwideBritish Journal of Ophthalmology, 2006
- Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic RetinopathyOphthalmology, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2006
- The biology of VEGF and its receptorsNature Medicine, 2003
- Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigenJournal of Molecular Biology, 1999
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971